作者
Donal McLornan, Richard Szydlo, Linda Koster, Yves Chalandon, Marie Robin, Christine Wolschke, Dietrich Beelen, Gerard Socié, Martin Bornhäuser, Emanuele Angelucci, Dietger Niederwieser, Arnim Gerbitz, Jürgen Finke, Antonin Vitek, Maija Itälä-Remes, Aleksandar Radujkovic, Lothar Kanz, Victoria Potter, Patrice Chevallier, Matthias Stelljes, Eefke Petersen, Stephen Robinson, Xavier Poire, Evgeny Klyuchnikov, Juan Carlos Hernández-Boluda, Tomasz Czerw, Patrick Hayden, Nicolaus Kröger, Ibrahim Yakoub-Agha
发表日期
2019/11/1
期刊
Biology of Blood and Marrow Transplantation
卷号
25
期号
11
页码范围
2167-2171
出版商
Elsevier
简介
This retrospective study by the European Society for Blood and Marrow Transplantation analyzed the outcome of 2224 patients with myelofibrosis (MF) who underwent allogeneic stem cell transplantation (allo-SCT) between 2000 and 2014; 781 (35%) underwent myeloablative conditioning (MAC) and 1443 (65%) reduced-intensity conditioning (RIC). Median patient age was 52.9 years (range, 18 to 74 years) and 57.5 years (range, 21 to 76 years) in the MAC and RIC cohorts, respectively. Donor type was similar: matched sibling donors (MAC, 317 [41%]; RIC, 552 [38%]) and unrelated donors (MAC, 464 [59%]; RIC, 891 [62%]). Median time to both neutrophil and platelet (>20 × 109/L) engraftment did not differ between cohorts. Rates of grade II to IV acute GVHD were 28% (MAC) and 31% (RIC; P = NS). Cumulative chronic GVHD rates (limited/extensive) were 22%/27% (MAC) and 19%/31% (RIC; P = .10 …
学术搜索中的文章
D McLornan, R Szydlo, L Koster, Y Chalandon… - Biology of Blood and Marrow Transplantation, 2019
